Reduced Prostasin (CAP1/PRSS8) Activity Eliminates HAI-1 and HAI-2 Deficiency–Associated Developmental Defects by Preventing Matriptase Activation

English version České info

Loss of either hepatocyte growth factor activator inhibitor (HAI)-1 or -2 is associated with embryonic lethality in mice, which can be rescued by the simultaneous inactivation of the membrane-anchored serine protease, matriptase, thereby demonstrating that a matriptase-dependent proteolytic pathway is a critical developmental target for both protease inhibitors. Here, we performed a genetic epistasis analysis to identify additional components of this pathway by generating mice with combined deficiency in either HAI-1 or HAI-2, along with genes encoding developmentally co-expressed candidate matriptase targets, and screening for the rescue of embryonic development. Hypomorphic mutations in Prss8, encoding the GPI-anchored serine protease, prostasin (CAP1, PRSS8), restored placentation and normal development of HAI-1–deficient embryos and prevented early embryonic lethality, mid-gestation lethality due to placental labyrinth failure, and neural tube defects in HAI-2–deficient embryos. Inactivation of genes encoding c-Met, protease-activated receptor-2 (PAR-2), or the epithelial sodium channel (ENaC) alpha subunit all failed to rescue embryonic lethality, suggesting that deregulated matriptase-prostasin activity causes developmental failure independent of aberrant c-Met and PAR-2 signaling or impaired epithelial sodium transport. Furthermore, phenotypic analysis of PAR-1 and matriptase double-deficient embryos suggests that the protease may not be critical for focal proteolytic activation of PAR-2 during neural tube closure. Paradoxically, although matriptase auto-activates and is a well-established upstream epidermal activator of prostasin, biochemical analysis of matriptase- and prostasin-deficient placental tissues revealed a requirement of prostasin for conversion of the matriptase zymogen to active matriptase, whereas prostasin zymogen activation was matriptase-independent.

Vyšlo v časopise: Reduced Prostasin (CAP1/PRSS8) Activity Eliminates HAI-1 and HAI-2 Deficiency–Associated Developmental Defects by Preventing Matriptase Activation. PLoS Genet 8(8): e32767. doi:10.1371/journal.pgen.1002937
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.pgen.1002937

Souhrn

Zdroje

1. SzaboR, BuggeTH (2011) Membrane anchored serine proteases in cell and developmental biology. Annu Rev Cell and Developmental Biology 27: 213–235.

2. BuggeTH, AntalisTM, WuQ (2009) Type II transmembrane serine proteases. J Biol Chem 284: 23177–23181.

3. AntalisTM, BuzzaMS, HodgeKM, HooperJD, Netzel-ArnettS (2010) The cutting edge: membrane-anchored serine protease activities in the pericellular microenvironment. Biochem J 428: 325–346.

4. GuipponiM, TanJ, CannonPZ, DonleyL, CrewtherP, et al. (2007) Mice deficient for the type II transmembrane serine protease, TMPRSS1/hepsin, exhibit profound hearing loss. Am J Pathol 171: 608–616.

5. ScottHS, KudohJ, WattenhoferM, ShibuyaK, BerryA, et al. (2001) Insertion of beta-satellite repeats identifies a transmembrane protease causing both congenital and childhood onset autosomal recessive deafness. Nat Genet 27: 59–63.

6. FasquelleL, ScottHS, LenoirM, WangJ, RebillardG, et al. (2010) Tmprss3, a transmembrane serine protease deficient in human DFNB8/10 deafness, is critical for Cochlear hair cell survival at the onset of hearing. J Biol Chem 286: 17383–17397.

7. ListK, SzaboR, WertzPW, SegreJ, HaudenschildCC, et al. (2003) Loss of proteolytically processed filaggrin caused by epidermal deletion of Matriptase/MT-SP1. J Cell Biol 163: 901–910.

8. LeyvrazC, CharlesRP, RuberaI, GuitardM, RotmanS, et al. (2005) The epidermal barrier function is dependent on the serine protease CAP1/Prss8. J Cell Biol 170: 487–496.

9. BuzzaMS, Netzel-ArnettS, Shea-DonohueT, ZhaoA, LinCY, et al. (2010) Membrane-anchored serine protease matriptase regulates epithelial barrier formation and permeability in the intestine. Proc Natl Acad Sci U S A 107: 4200–4205.

10. ListK, KosaP, SzaboR, BeyAL, WangCB, et al. (2009) Epithelial integrity is maintained by a matriptase-dependent proteolytic pathway. Am J Pathol 175: 1453–1463.

11. ZhengXL, KitamotoY, SadlerJE (2009) Enteropeptidase, a type II transmembrane serine protease. Front Biosci (Elite Ed) 1: 242–249.

12. DriesDL, VictorRG, RameJE, CooperRS, WuX, et al. (2005) Corin gene minor allele defined by 2 missense mutations is common in blacks and associated with high blood pressure and hypertension. Circulation 112: 2403–2410.

13. WangW, LiaoX, FukudaK, KnappeS, WuF, et al. (2008) Corin variant associated with hypertension and cardiac hypertrophy exhibits impaired zymogen activation and natriuretic peptide processing activity. Circ Res 103: 502–508.

14. YanW, WuF, MorserJ, WuQ (2000) Corin, a transmembrane cardiac serine protease, acts as a pro-atrial natriuretic peptide-converting enzyme. Proc Natl Acad Sci U S A 97: 8525–8529.

15. DuX, SheE, GelbartT, TruksaJ, LeeP, et al. (2008) The serine protease TMPRSS6 is required to sense iron deficiency. Science 320: 1088–1092.

16. FinbergKE, HeeneyMM, CampagnaDR, AydinokY, PearsonHA, et al. (2008) Mutations in TMPRSS6 cause iron-refractory iron deficiency anemia (IRIDA). Nat Genet 40: 569–571.

17. Netzel-ArnettS, BuggeTH, HessRA, CarnesK, StringerBW, et al. (2009) The glycosylphosphatidylinositol-anchored serine protease PRSS21 (testisin) imparts murine epididymal sperm cell maturation and fertilizing ability. Biol Reprod 81: 921–932.

18. KawanoN, KangW, YamashitaM, KogaY, YamazakiT, et al. (2010) Mice lacking two sperm serine proteases, ACR and PRSS21, are subfertile, but the mutant sperm are infertile in vitro. Biol Reprod 83: 359–369.

19. Heinz-ErianP, MullerT, KrabichlerB, SchranzM, BeckerC, et al. (2009) Mutations in SPINT2 Cause a Syndromic Form of Congenital Sodium Diarrhea. Am J Hum Genet 84: 188–196.

20. SzaboR, KosaP, ListK, BuggeTH (2009) Loss of matriptase suppression underlies spint1 mutation-associated ichthyosis and postnatal lethality. Am J Pathol 174: 2015–2022.

21. NagaikeK, KawaguchiM, TakedaN, FukoshimaT, SawaguchiA, et al. (2008) Defect of hepatocyte growth factor activator inhibitor type 1/serine protease inhibior, Kunitz type 1 (Hai-1/Spint1) leads to ichthyosis-like condition and abnormal hair development in mice. American Journal of Pathology 173: 1–12.

22. KawaguchiM, TakedaN, HoshikoS, YoritaK, BabaT, et al. (2011) Membrane-bound serine protease inhibitor HAI-1 is required for maintenance of intestinal epithelial integrity. Am J Pathol 179: 1815–1826.

23. ListK, CurrieB, ScharschmidtTC, SzaboR, ShiremanJ, et al. (2007) Autosomal ichthyosis with hypotrichosis syndrome displays low matriptase proteolytic activity and is phenocopied in ST14 hypomorphic mice. J Biol Chem 282: 36714–36723.

24. AlefT, TorresS, HausserI, MetzeD, TursenU, et al. (2009) Ichthyosis, Follicular Atrophoderma, and Hypotrichosis Caused by Mutations in ST14 Is Associated with Impaired Profilaggrin Processing. J Invest Dermatol 129: 862–869.

25. ChenYW, WangJK, ChouFP, ChenCY, RorkeEA, et al. (2010) Regulation of the matriptase-prostasin cell surface proteolytic cascade by hepatocyte growth factor activator inhibitor-1 during epidermal differentiation. J Biol Chem 285: 31755–31762.

26. Netzel-ArnettS, CurrieBM, SzaboR, LinCY, ChenLM, et al. (2006) Evidence for a matriptase-prostasin proteolytic cascade regulating terminal epidermal differentiation. J Biol Chem 281: 32941–32945.

27. KimC, LeeHS, LeeD, LeeSD, ChoEG, et al. (2011) Epithin/PRSS14 proteolytically regulates angiopoietin receptor Tie2 during transendothelial migration. Blood 117: 1415–1424.

28. UstachCV, HuangW, Conley-LaCombMK, LinCY, CheM, et al. (2010) A novel signaling axis of matriptase/PDGF-D/ss-PDGFR in human prostate cancer. Cancer Res 70: 9631–9640.

29. LeeSL, DicksonRB, LinCY (2000) Activation of hepatocyte growth factor and urokinase/plasminogen activator by matriptase, an epithelial membrane serine protease. J Biol Chem 275: 36720–36725.

30. OwenKA, QiuD, AlvesJ, SchumacherAM, KilpatrickLM, et al. (2010) Pericellular activation of hepatocyte growth factor by the transmembrane serine proteases matriptase and hepsin, but not by the membrane-associated protease uPA. Biochem J 426: 219–228.

31. TakeuchiT, HarrisJL, HuangW, YanKW, CoughlinSR, et al. (2000) Cellular localization of membrane-type serine protease 1 and identification of protease-activated receptor-2 and single-chain urokinase-type plasminogen activator as substrates. J Biol Chem 275: 26333–26342.

32. BhattAS, WelmA, FaradyCJ, VasquezM, WilsonK, et al. (2007) Coordinate expression and functional profiling identify an extracellular proteolytic signaling pathway. Proc Natl Acad Sci USA 104: 5771–5776.

33. BhattAS, Erdjument-BromageH, TempstP, CraikCS, MoasserMM (2005) Adhesion signaling by a novel mitotic substrate of src kinases. Oncogene 24: 5333–5343.

34. VuagniauxG, ValletV, JaegerNF, HummlerE, RossierBC (2002) Synergistic activation of ENaC by three membrane-bound channel-activating serine proteases (mCAP1, mCAP2, and mCAP3) and serum- and glucocorticoid-regulated kinase (Sgk1) in Xenopus Oocytes. J Gen Physiol 120: 191–201.

35. AndreasenD, VuagniauxG, Fowler-JaegerN, HummlerE, RossierBC (2006) Activation of epithelial sodium channels by mouse channel activating proteases (mCAP) expressed in Xenopus oocytes requires catalytic activity of mCAP3 and mCAP2 but not mCAP1. J Am Soc Nephrol 17: 968–976.

36. JinX, YagiM, AkiyamaN, HirosakiT, HigashiS, et al. (2006) Matriptase activates stromelysin (MMP-3) and promotes tumor growth and angiogenesis. Cancer Sci 97: 1327–1334.

37. KilpatrickLM, HarrisRL, OwenKA, BassR, GhorayebC, et al. (2006) Initiation of plasminogen activation on the surface of monocytes expressing the type II transmembrane serine protease matriptase. Blood 108: 2616–2623.

38. ListK, HaudenschildCC, SzaboR, ChenW, WahlSM, et al. (2002) Matriptase/MT-SP1 is required for postnatal survival, epidermal barrier function, hair follicle development, and thymic homeostasis. Oncogene 21: 3765–3779.

39. ListK, SzaboR, MolinoloA, NielsenBS, BuggeTH (2006) Delineation of matriptase protein expression by enzymatic gene trapping suggests diverging roles in barrier function, hair formation, and squamous cell carcinogenesis. Am J Pathol 168: 1513–1525.

40. SzaboR, MolinoloA, ListK, BuggeTH (2007) Matriptase inhibition by hepatocyte growth factor activator inhibitor-1 is essential for placental development. Oncogene 26: 1546–1556.

41. FanB, BrennanJ, GrantD, PealeF, RangellL, et al. (2007) Hepatocyte growth factor activator inhibitor-1 (HAI-1) is essential for the integrity of basement membranes in the developing placental labyrinth. Dev Biol 303: 222–230.

42. TanakaH, NagaikeK, TakedaN, ItohH, KohamaK, et al. (2005) Hepatocyte Growth Factor Activator Inhibitor Type 1 (HAI-1) Is Required for Branching Morphogenesis in the Chorioallantoic Placenta. Mol Cell Biol 25: 5687–5698.

43. SzaboR, HobsonJP, ChristophK, KosaP, ListK, et al. (2009) Regulation of cell surface protease matriptase by HAI2 is essential for placental development, neural tube closure and embryonic survival in mice. Development 136: 2653–2663.

44. MitchellKJ, PinsonKI, KellyOG, BrennanJ, ZupicichJ, et al. (2001) Functional analysis of secreted and transmembrane proteins critical to mouse development. Nat Genet 28: 241–249.

45. CamererE, BarkerA, DuongDN, GanesanR, KataokaH, et al. (2010) Local protease signaling contributes to neural tube closure in the mouse embryo. Dev Cell 18: 25–38.

46. SzaboR, RasmussenAL, MoyerAB, KosaP, SchaferJ, et al. (2011) c-Met-induced epithelial carcinogenesis is initiated by the serine protease matriptase. Oncogene 30: 2003–2016.

47. BladtF, RiethmacherD, IsenmannS, AguzziA, BirchmeierC (1995) Essential role for the c-met receptor in the migration of myogenic precursor cells into the limb bud. Nature 376: 768–771.

48. UeharaY, MinowaO, MoriC, ShiotaK, KunoJ, et al. (1995) Placental defect and embryonic lethality in mice lacking hepatocyte growth factor/scatter factor. Nature 373: 702–705.

49. SpacekDV, PerezAF, FerrantiKM, WuLK, MoyDM, et al. (2010) The mouse frizzy (fr) and rat ‘hairless’ (frCR) mutations are natural variants of protease serine S1 family member 8 (Prss8). Exp Dermatol 19: 527–532.

50. HedstromL (2002) Serine protease mechanism and specificity. Chem Rev 102: 4501–4524.

51. RossierBC, StuttsMJ (2009) Activation of the epithelial sodium channel (ENaC) by serine proteases. Annu Rev Physiol 71: 361–379.

52. PlanesC, RandrianarisonNH, CharlesR-P, FrateschiS, CluzeeaudD, et al. (2009) ENaC-mediated alveolar fluid clearance and lung fluid balance depend on the channel-activating protease 1. EMBO Molecular Medicine 2: 26–37.

53. MillerTA, ScottWJJr (1992) Abnormalities in ureter and kidney development in mice given acetazolamide-amiloride or dimethadione (DMO) during embryogenesis. Teratology 46: 541–550.

54. CanessaCM, SchildL, BuellG, ThorensB, GautschiI, et al. (1994) Amiloride-sensitive epithelial Na+ channel is made of three homologous subunits. Nature 367: 463–467.

55. HummlerE, BarkerP, GatzyJ, BeermannF, VerdumoC, et al. (1996) Early death due to defective neonatal lung liquid clearance in alpha-ENaC-deficient mice. Nat Genet 12: 325–328.

56. OberstMD, WilliamsCA, DicksonRB, JohnsonMD, LinCY (2003) The activation of matriptase requires its noncatalytic domains, serine protease domain, and its cognate inhibitor. J Biol Chem 278: 26773–26779.

57. ShipwayA, DanahayH, WilliamsJA, TullyDC, BackesBJ, et al. (2004) Biochemical characterization of prostasin, a channel activating protease. Biochem Biophys Res Commun 324: 953–963.

58. DendaK, ShimomuraT, KawaguchiT, MiyazawaK, KitamuraN (2002) Functional characterization of Kunitz domains in hepatocyte growth factor activator inhibitor type 1. J Biol Chem 277: 14053–14059.

59. KirchhoferD, PeekM, LipariMT, BilleciK, FanB, et al. (2005) Hepsin activates pro-hepatocyte growth factor and is inhibited by hepatocyte growth factor activator inhibitor-1B (HAI-1B) and HAI-2. FEBS Lett 579: 1945–1950.

60. KirchhoferD, PeekM, LiW, StamosJ, EigenbrotC, et al. (2003) Tissue expression, protease specificity, and Kunitz domain functions of hepatocyte growth factor activator inhibitor-1B (HAI-1B), a new splice variant of HAI-1. J Biol Chem 278: 36341–36349.

61. HerterS, PiperDE, AaronW, GabrieleT, CutlerG, et al. (2005) Hepatocyte growth factor is a preferred in vitro substrate for human hepsin, a membrane-anchored serine protease implicated in prostate and ovarian cancers. Biochem J 390: 125–136.

62. FanB, WuTD, LiW, KirchhoferD (2005) Identification of hepatocyte growth factor activator inhibitor-1B as a potential physiological inhibitor of prostasin. J Biol Chem 280: 34513–34520.

63. DelariaKA, MullerDK, MarlorCW, BrownJE, DasRC, et al. (1997) Characterization of placental bikunin, a novel human serine protease inhibitor. J Biol Chem 272: 12209–12214.

64. QinL, DendaK, ShimomuraT, KawaguchiT, KitamuraN (1998) Functional characterization of Kunitz domains in hepatocyte growth factor activator inhibitor type 2. FEBS Lett 436: 111–114.

65. CoppAJ, GreeneND (2010) Defining a PARticular pathway of neural tube closure. Dev Cell 18: 1–2.

66. HummlerE, MerillatAM, RuberaI, RossierBC, BeermannF (2002) Conditional gene targeting of the Scnn1a (alphaENaC) gene locus. Genesis 32: 169–172.

67. ConnollyAJ, IshiharaH, KahnML, FareseRVJr, CoughlinSR (1996) Role of the thrombin receptor in development and evidence for a second receptor. Nature 381: 516–519.

68. LindnerJR, KahnML, CoughlinSR, SambranoGR, SchaubleE, et al. (2000) Delayed onset of inflammation in protease-activated receptor-2- deficient mice. J Immunol 165: 6504–6510.

69. OberstMD, ChenLL, KiyomiyaK-I, WilliamsCA, LeeM-S, et al. (2005) HAI-1 regulates activation and expression of matriptase, a membrane-bound serine protease. Am J Physiol Cell Physiol 289: C462–C470.